Venture Life (VLG) AI Stock Analysis

• Market Cap: £71.71M
• Dividend Yield: N/A
• Average Volume (3M): 219.28K
• Price to Earnings (P/E): 94.9
• Beta (1Y): 0.24
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 165
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 128,052,300
• 10 Day Avg. Volume: 128,796
• 30 Day Avg. Volume: 219,278
• PEG Ratio: 1.18
• Price to Book (P/B): 0.66
• Price to Sales (P/S): 1.87
• P/FCF Ratio: 5.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: 57.00p ▲(1.79% Upside)

Venture Life's overall stock score is primarily impacted by financial performance challenges, including declining revenues and profitability. Technical analysis indicates a lack of strong momentum, and the high P/E ratio suggests overvaluation concerns. The absence of earnings call data and corporate events means these factors do not influence the score.

Venture Life Business Overview & Revenue Model

Company Description

Venture Life Group (VLG) is a UK-based company specializing in the development and commercialization of products that enhance the quality of life for consumers, with a focus on the health and personal care sectors. The company offers a range of products including medical devices, skincare, and dietary supplements, primarily targeting aging populations and individuals seeking to improve their health and well-being. VLG operates through its proprietary brands and also provides contract manufacturing and development services to third parties.

How the Company Makes Money

Venture Life generates revenue through several key streams. Primarily, the company earns income from the sale of its branded products, which include over-the-counter healthcare and personal care items. Additionally, VLG has a significant revenue stream from contract manufacturing services, where it produces products for third-party companies under their brands, leveraging its expertise and facilities. Partnerships with retailers and distributors enhance its market reach and sales volume. The company's focus on product innovation and regulatory compliance also allows it to capture market opportunities in the health and wellness industry, contributing to its overall earnings.

Venture Life Financial Statement Overview

Summary

Venture Life faces challenges in maintaining revenue and profitability, as seen in the income statement. However, balance sheet strength and improving cash flows provide some financial resilience. The company needs to address declining revenues and margins to improve its financial health.

Income Statement

The company shows a declining revenue trend with a significant drop from 2023 to 2024. Gross Profit and Net Income margins are under pressure, turning negative in 2024, indicating profitability issues. The EBIT and EBITDA margins remain positive but have decreased, reflecting operational challenges.

Balance Sheet

The balance sheet reflects a stable equity base with a manageable debt-to-equity ratio. However, a slight increase in liabilities over time may pose a risk to financial stability. The equity ratio remains healthy, suggesting a strong asset base relative to liabilities.

Cash Flow

The cash flow statement shows improvement in free cash flow in recent years, indicating better cash generation despite declining net income. Operating cash flow remains robust relative to net income, suggesting efficient cash operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	26.59M	51.41M	43.98M	32.76M	30.08M
Gross Profit	12.19M	20.15M	17.66M	12.96M	12.85M
EBITDA	4.32M	9.95M	7.61M	5.16M	5.60M
Net Income	-314.00K	921.00K	520.00K	2.40M	2.37M
Balance Sheet
Total Assets	124.49M	119.50M	125.29M	103.63M	92.68M
Cash, Cash Equivalents and Short-Term Investments	3.05M	5.62M	5.63M	5.24M	42.09M
Total Debt	23.86M	24.39M	26.85M	12.73M	11.18M
Total Liabilities	49.08M	43.24M	49.63M	30.47M	20.57M
Stockholders Equity	75.41M	76.25M	75.66M	73.16M	72.11M
Cash Flow
Free Cash Flow	8.34M	5.81M	1.36M	-2.66M	637.00K
Operating Cash Flow	8.35M	8.22M	5.57M	601.00K	2.71M
Investing Cash Flow	-11.29M	-5.34M	-11.69M	-39.18M	-7.53M
Financing Cash Flow	1.78M	-2.81M	6.92M	1.50M	36.27M

Venture Life Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 56.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VLG, the sentiment is Positive. The current price of 56 is above the 20-day moving average (MA) of 54.89, below the 50-day MA of 56.38, and above the 200-day MA of 49.57, indicating a neutral trend. The MACD of -0.33 indicates Negative momentum. The RSI at 53.27 is Neutral, neither overbought nor oversold. The STOCH value of 46.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:VLG.

Venture Life Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
EAH	―	£56.24M	33.33	1.99%	―	-10.99%	60.65%
ANCR	―	£173.16M	-7.08	2.83%	2.07%	8.74%	-166.50%
AGY	―	£531.23M	―	―	―	4.50%	74.32%
VLG	―	£71.71M	94.92	―	―	―	―

Venture Life Corporate Events

Venture Life Director Increases Stake in Company

Venture Life Group PLC announced that Mark Adams, a Non-Executive Director, has purchased 88,999 ordinary shares of the company, increasing his total holdings to 308,897 shares, which represents approximately 0.24% of the company’s issued share capital. This transaction underscores the confidence of the company’s leadership in its market position and future prospects, potentially influencing stakeholder perceptions and market dynamics.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £56.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Group Initiates Share Buyback Programme to Boost Shareholder Value

Venture Life Group PLC has announced a share buyback programme following the release of its interim results for the first half of 2025. The company believes its shares are undervalued and aims to enhance earnings per share and shareholder value through this programme, which will be funded by existing cash resources. The buyback will involve repurchasing up to 10% of the company’s issued share capital by July 2026, managed by Cavendish Capital Markets Limited. This move is expected to strengthen Venture Life’s market position and potentially increase its stock value, although the programme’s completion is not guaranteed and may be adjusted based on market conditions.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £60.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Group Reports Strong Revenue Growth and Strategic Divestments

Venture Life Group PLC announced robust financial results for the first half of 2025, with a 43.1% increase in group revenue and a significant improvement in gross profit. The company has strategically divested its contract development and manufacturing operations and certain non-core products, raising €62 million in cash, which positions it as a higher margin, brand-focused consumer healthcare business. With a net cash position of £34.1 million, Venture Life plans to invest in organic and acquired growth, launch a share buyback program, and pursue potential mergers and acquisitions, enhancing its market positioning and operational efficiency.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £60.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Group Announces Live Interim Results Presentation

Venture Life Group PLC announced that CEO Jerry Randall and CFO Daniel Wells will present the company’s Interim Results for the period ended 30 June 2025 via a live presentation on Investor Meet Company. This event, scheduled for 01 October 2025, is open to all existing and potential shareholders, allowing them to submit questions and engage with the company’s leadership. This initiative reflects Venture Life’s commitment to transparency and stakeholder engagement, potentially enhancing investor relations and market confidence.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £60.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Venture Life Group Adjusts Accounting Reference Date to Enhance Strategic Alignment

Venture Life Group PLC, a leader in the global consumer healthcare sector, has announced a change in its accounting reference date from 31 December to 31 May to better align with its revised strategy. This change aims to reduce revenue seasonality and manage specific operating costs more effectively, impacting the company’s financial calendar with new dates for publishing unaudited interim and audited accounts.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £60.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.